Wilhelm Krek was one of TOLREMO’s co-founders and was Full Professor of Cell Biology at ETH Zurich since 2003. He was a world-leader in cancer cell signaling and had worked at the Friedrich Miescher Institute for Biomedical Research (FMI), Basel, and at the Dana Farber Cancer Institute/Harvard Medical School in Boston. He also co-founded the ETH Spin-off ProteoMedix AG, the Institute of Molecular Health Sciences, and the NEXUS Personalized Health Technologies Platform at ETH Zurich. For his work on cell signaling and disease mechanisms, he received several honors including the Robert Wenner Prize, the Friedrich Miescher Medal, the International Steiner Cancer Research Award and the Swiss Bridge Award. He was elected member of EMBO and the American Association for Cancer Research.
Willy was instrumental in laying the scientific foundation for the novel scientific principles that TOLRMEO is based on. Despite his untimely passing, his contagious enthusiasm, his passion for science, and his visionary thinking will remain at the heart of the company.